Actively Recruiting
To Investigate the Mechanism of Novel Molecular Probe [18F]AV45(Ab2) and [18F]AV1451(Tau)PET/CT in the Diagnosis of Early Pathological Changes of Alzheimer's Disease
Led by Sichuan Provincial People's Hospital · Updated on 2025-02-19
280
Participants Needed
1
Research Sites
N/A
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are investigating the early brain regions involved in Alzheimer's disease and its precursors using novel molecular probes [18F]AV45 (Ab2) and [18F]AV1451 (Tau) with PET/CT imaging. This study aims to understand the distribution of positive brain lesions affecting mental state tests like the simple mental state examination and the Montreal Cognitive Assessment Scale in Alzheimer's patients. The goal is to provide molecular imaging information that may help study Alzheimer's disease mechanisms and establish objective diagnostic criteria for early detection. The study uses new imaging agents Ab2 and Tau PET/CT, which can detect pathological changes at the molecular level before symptoms appear. These molecular probes offer earlier and more visual detection of Alzheimer's disease-related changes, helping to define positive diagnostic criteria for early Alzheimer's disease. Participants include groups with mild cognitive impairment, Alzheimer's disease, and healthy volunteers. Participants will be assessed through PET/CT imaging using these molecular probes to observe brain pathology. Researchers will evaluate the diagnostic criteria for Ab2 and Tau imaging within two months. The study includes cognitive tests and clinical dementia rating scales. This observational study involves healthy volunteers and patients with mild cognitive impairment or Alzheimer's disease, aiming to improve early diagnosis through imaging techniques.
CONDITIONS
Brief Title
[18F]AV45(Aβ) and [18F]AV1451(Tau)PET/CT in the Diagnosis of Early Pathological Changes of Alzheimer's Disease
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Meet the mild cognitive impairment (MCI) diagnostic criteria of Peterson (2004)
- Clinical Dementia Rating (CDR) score of 0.5 for MCI participants
- Prominent memory loss possibly with other cognitive impairments
- Insidious onset and slow progression
- Not at the level of dementia
- Meet Alzheimer's disease diagnostic criteria as per DSM-IV-R, NINCDS-ADRDA, or NIA-AA
- Clinical Dementia Rating (CDR) score of 1 point for Alzheimer's disease participants
You will not qualify if you...
- History of stroke or focal neurological signs with imaging showing small cerebral vascular disease (Fazekas score 2)
- Other neurological disorders causing brain dysfunction such as depression, brain tumors, Parkinson's disease, metabolic encephalopathy, encephalitis, multiple sclerosis, epilepsy, brain trauma, or normal pressure hydrocephalus
- Systemic diseases causing cognitive impairment like liver or kidney failure, thyroid dysfunction, severe anemia, folic acid or vitamin B12 deficiency, syphilis, HIV infection, alcohol or drug abuse
- Mental and neurological retardation
- Other diseases known to cause cognitive impairment
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to 2 months
Participants undergo PET/CT imaging using the molecular probes [18F]AV45(Aβ) and [18F]AV1451(Tau) to investigate early pathological changes of Alzheimer's disease.
1 to 2 imaging visits depending on participant group
Duration - Up to 2 months
Participants are observed following imaging to establish diagnostic criteria and monitor outcomes.
Follow-up assessments may occur as scheduled
Trial Site Locations
Total: 1 location
1
Departments of Nuclear Medicine, Sichuan Provincial People's Hospital
Chengdu, Sichuan, China, 610072
Actively Recruiting
Research Team
H
Hao Wang
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
3
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here